10q10k10q10k.net
Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc.ELTXEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies leveraging its proprietary amphiphile technology platform. Its pipeline includes targeted cancer vaccines and immunomodulatory candidates addressing both solid tumors and hematological malignancies, serving global oncology patient communities.

Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022

Revenue

$0

Gross Profit

N/A

Operating Profit

$-5.8M

Net Profit

$-7.2M

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

YoY Growth

N/A

EPS

$-22.67

Elicio Therapeutics, Inc. Q3 FY2022 Financial Summary

Elicio Therapeutics, Inc. reported revenue of $0 for Q3 FY2022, with a net profit of $-7.2M (up 54.2% YoY) (N/A margin).

Key Financial Metrics

Total Revenue$0
Net Profit$-7.2M
Gross MarginN/A
Operating MarginN/A
Report PeriodQ3 FY2022

Elicio Therapeutics, Inc. Annual Revenue by Year

Elicio Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $2.3M).

YearAnnual Revenue
2022$2.3M

Elicio Therapeutics, Inc. Quarterly Revenue & Net Profit History

Elicio Therapeutics, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q1 FY2023$0—$-8.0MN/A
Q4 FY2022$0—$-6.7MN/A
Q3 FY2022$0—$-7.2MN/A
Q2 FY2022$653.0K+20.9%$-7.3M-1117.8%
Q1 FY2022$1.6M+344.2%$-7.1M-428.4%

Income Statement

Q1 2022Q2 2022Q3 2022Q4 2022Q1 2023
Revenue$1.6M$653000$0$0$0
YoY Growth344.2%20.9%N/AN/AN/A

Balance Sheet

Q1 2022Q2 2022Q3 2022Q4 2022Q1 2023
Assets$81.3M$70.8M$61.3M$22.7M$41.8M
Liabilities$14.1M$11.1M$11.1M$13.7M$2.1M
Equity$-81.4M$-88.6M$-95.7M$-102.1M$-109.9M

Cash Flow

Q1 2022Q2 2022Q3 2022Q4 2022Q1 2023
Operating CF$-15.7M$6.1M$-5.4M$-7.3M$-8.1M